Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
:BPTH
BPTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.12 - $7.67
Previous CloseN/A
Volume216.71K
Average Volume (3M)721.67K
Market Cap
$1.48M
Enterprise Value$2.21M
Total Cash (Recent Filing)$1.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
May 15, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding8,308,007
10 Day Avg. Volume107,017
30 Day Avg. Volume721,666
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.41
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.12 and its highest was $7.67 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $1.48M.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is May 15, 2025 which is in 63 days.
How were Bio-Path Holdings’s earnings last quarter?
Currently, no data Available
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate is -0.37.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 8,308,007 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
---
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
---
BPTH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Read More>---
BPTH Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering BPTH
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-80.41%
reiterated a buy rating 7 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -80.41% per trade.
---